<scp>NMOSD</scp> Revisited
Izumi Kawachi reports receiving funding for research, travel, and/or speaker's honoraria from Chugai Pharmaceuticals, Novartis Pharma, Biogen, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Teijin Pharma, Argenx, UCB, and Daiichi-Sankyo, and is a scientific advisory board member for UCB, Mitsubishi Tanabe Pharma, and Chugai Pharmaceuticals. She is a Guest Editor of Clinical and Experimental Neuroimmunology. The author has nothing to report.
Authors
- Izumi Kawachi (ORCID: https://orcid.org/0000-0002-7140-8500)
Institutions
- Niigata University Medical and Dental Hospital (JP)
- Niigata University (JP)
Publication Details
- Journal
- Clinical and Experimental Neuroimmunology
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1111/cen3.70025
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00